comparemela.com

Latest Breaking News On - Adcendo - Page 1 : comparemela.com

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

/PRNewswire/ Adcendo ApS ("Adcendo"), a biotech company focused on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of.

San diegoUnited statesLandskapet birkalandSouthwest finlandLars engelholmDominik mumbergCancer researchFinsen laboratoryAurexel life sciencesNovo holdingsClinical research immunologyUniversity of copenhagenCancer invasion section of the finsen laboratoryAmerican association for cancer researchAmerican associationAnnual meeting

Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline

/PRNewswire/ Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of.

John zhuMichael pehlNovo holdingsDuality biologicsDuality immune toxin antibody conjugatesOption license agreementChief executive officerYsios capitalPontifax venture capital

Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline

/PRNewswire/ Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of.

Michael pehlNovo holdingsPontifax venture capitalYsios capitalGilde healthcareOhad hammerAdcendo boardDevelopment candidate nominationChief executive officerCandidate nominationBoard director

Adcendo funding boosts antibody-drug conjugates development

Funds will be used to ensure the wider pan-sarcoma development of lead candidate uPARAP - News - PharmaTimes

Michael pehlNovo holdingsPontifax venture capitalYsios capitalGilde healthcareOhad hammer

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Adcendo licenses Duality's DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC programAgreement based on synergies between Adcendo and Duality in

John zhuKostenloser wertpapierhandelMichael pehlNovo holdingsDuality immune toxin antibody conjugatesDuality biologicsChief executive officerYsios capitalDuality immune modulating antibody conjugates

vimarsana © 2020. All Rights Reserved.